Is Addex Therapeutics Ltd (0QNV.L) a Buy, Sell, or Hold?
LSE : 0QNV.L
Addex Therapeutics Ltd
$0.0402 CHF
$0.0 (-4.29%)
- Volume
- 20K
- Average Volume
- 140K
- Market Capitalization
- $1.06M
- P/E Ratio
- -0.75
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.08
- Year Low
- $0.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.97
Company Overview
LSE
Timothy Mark Dyer
Biotechnology
Healthcare
0QNV.L
23
CH
CHF
Liquidity Metrics
0.03
0.97
0.97
0.77
0.00
Sales & Valuation
$173K
69.83
2.15
-2.68
-0.01
Profitability
-$0.06
-$6.73M
-7775.20%
-7901.66%
-131.35%
-146.41%
P/E Metrics
-0.75
0.00
0.00
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-108.75
2/9
-$34907
$4.76M
$1.47M
-$3.91M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Lénaic Teyssédou | Head of Finance |
| Roger G. Mills | Chief Medical Officer & Director |
| Mikhail Kalinichev | Head of Translational Science |
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Addex Therapeutics Ltd (LSE:0QNV.L) Stock
Addex Therapeutics Ltd is a biopharmaceutical firm based in Switzerland, dedicated to identifying, developing, and commercializing small-molecule pharmaceutical products designed to address central nervous system (CNS) disorders. The company's primary research endeavor involves discovering oral small-molecule allosteric modulators of G-protein coupled receptors. Its leading development programs feature Dipraglurant, an investigational therapy for levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, aimed at epilepsy and other unspecified CNS conditions; and a GABAB PAM candidate for the treatment of addiction. Addex Therapeutics maintains licensing and collaborative agreements with partners including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–To ... oth Association. Established in 2002, the company, headquartered in Geneva, Switzerland, was formerly known as Addex Pharmaceuticals Ltd before adopting its current name in March 2012.
Frequently Asked Questions
-
What is the current Addex Therapeutics Ltd (0QNV.L) stock price?
-
Addex Therapeutics Ltd(LSE:0QNV.L) stock price is $0.0402 in the last trading session. During the trading session, 0QNV.L stock reached the peak price of $0.0763 while $0.0402 was the lowest point it dropped to. The percentage change in 0QNV.L stock occurred in the recent session was --4.29% while the dollar amount for the price change in 0QNV.L stock was -$0.0.
-
0QNV.L's industry and sector of operation?
-
The LSE listed 0QNV.L is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 0QNV.L?
-
Lénaic Teyssédou | Head of Finance
Roger G. Mills | Chief Medical Officer & Director
Mikhail Kalinichev | Head of Translational Science
Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director
| -
How many employees does 0QNV.L have?
-
Number of 0QNV.L employees currently stands at 23. 0QNV.L operates from Chemin des Mines, 9, Geneva, None 1202, CH.
-
Link for 0QNV.L official website?
-
Official Website of 0QNV.L is: https://www.addextherapeutics.com
-
How do I contact 0QNV.L?
-
0QNV.L could be contacted at phone #41 22 884 1555 and can also be accessed through its website. 0QNV.L operates from Chemin des Mines, 9, Geneva, None 1202, CH.
-
How many shares of 0QNV.L are traded daily?
-
The average number of 0QNV.L shares traded daily for last 3 months was 140K.
-
What is the market cap of 0QNV.L currently?
-
The market value of 0QNV.L currently stands at $1.06M with its latest stock price at $0.0402